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Abstract
The use of primary care databases has been integral in pharmacoepidemiological studies and pharmacovigilance. Primary 
care databases derive from electronic health records and offer a comprehensive description of aggregate patient data, from 
demography to medication history, and good sample sizes. Studies using these databases improve our understanding of 
prescribing characteristics and associated risk factors to facilitate better patient care, but there are limitations. We describe 
eight key scenarios where study data outcomes can be affected by absent prescriptions in UK primary care databases: (1) 
out-of-hours, urgent care and acute care prescriptions; (2) specialist-only prescriptions; (3) alternative community prescrib-
ing, such as pharmacy, family planning clinic or sexual health clinic medication prescriptions; (4) newly licensed medica-
tion prescriptions; (5) medications that do not require prescriptions; (6) hospital inpatient and outpatient prescriptions; (7) 
handwritten prescriptions; and (8) private pharmacy and private doctor prescriptions. The significance of each scenario is 
dependent on the type of medication under investigation, nature of the study and expected outcome measures. We recom-
mend that all researchers using primary care databases be aware of the potential for missing prescribing data and be sensitive 
to how this can vary substantially between items, drug classes, patient groups and over time. Close liaison with practising 
primary care clinicians in the UK is often essential to ensure awareness of nuances in clinical practice.
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Key Points 
Databases derived from digital patient records can pro-
vide valuable information about patient care.
Since primary care accounts for a majority of patient 
contacts in the healthcare setting, prescribing data from 
this setting can improve patient care in a number of 
ways, such as monitoring prescribing practice to improve 
drug safety.
Best use of primary care prescribing data requires an 
appreciation of clinical practice, standards and culture 
within primary care.
1 Introduction
Routinely collated primary care data from electronic health 
records (EHRs) are the most frequently used data source 
for research into medical prescribing practices and pharma-
covigilance and pharmacoepidemiological studies [1]. The 
use of EHRs in the United Kingdom (UK) was initiated in 
primary care, with 96% of all general practices using them 
by 1996 [2]. Currently, all UK-wide general practice con-
sultations are recorded within EHRs [3]. Hence, we have 
a vast repository of health data that spans decades and has 
enormous value for patient safety, quality improvement and 
cost-effectiveness research [4]. Primary care databases such 
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as those managed by the Secure Anonymised Information 
Linkage (SAIL) Databank [5], The Health Improvement 
Network (THIN) [6] and the Clinical Practice Research 
Datalink (CPRD) are a rich source of patient data. For 
example, CPRD is a UK-wide network of over 2000 general 
practices and includes over 60 million patients, of which 16 
million were actively registered as of May 2021. It provides 
longitudinal data, with 20 years of follow-up for 25% of 
patients [7]. In June 2020, there were over 2700 publica-
tions investigating drug safety, use of medicines, effective-
ness of health policy, healthcare delivery and disease risk 
factors using CPRD [8]. The wealth of prescribing infor-
mation from such routinely collated primary care datasets 
is undeniable, but there are several scenarios to consider 
where the data can be susceptible to misinterpretation due 
to absent prescriptions. This review will describe eight key 
scenarios resulting in absent prescription data that can sig-
nificantly affect outcomes and interpretation of research 
findings. The relevance of each scenario will vary based 
on the type of research and drug(s) under investigation.
2  Common Scenarios Where Prescription 
Data are Absent
2.1  Scenario I: Out‑of‑Hours, Urgent Care and Acute 
Care Prescriptions
Out-of-hours primary care services are a fundamental 
part of primary care provision in the UK. These providers 
manage cases that would have been seen by their general 
practice had they presented in normal hours, which is usu-
ally between 0800 hours and 1830 hours on weekdays, 
excluding bank holidays [9]. Demand for out-of-hours 
and urgent care services has risen consistently over the 
last 5 years, possibly due to increased patient numbers, 
organisational restructuring and funding issues within the 
National Health Service (NHS) [10]. Out-of-hours and 
urgent care prescriptions are rarely included in primary 
care databases as these settings may not have authorization 
to update patients’ primary care EHR. Potential absence 
of prescriptions due to out-of-hours prescribing is particu-
larly relevant in studies investigating the management of 
acute infections and medication adherence for chronic dis-
ease. A study found that 23.7% of all out-of-hours encoun-
ters resulted in antibiotic prescriptions [11]. Another study 
found that, up to 30% of all calls to out-of-hours week-
end services over a single day were documented as urgent 
requests for repeat medication for chronic disease manage-
ment [8]. Since out-of-hours prescribing is not routinely 
recorded in the primary care EHR prescribing data, the 
clinical concern here is disruption of medication moni-
toring for prescribing safety due to interruptions in the 
general practice prescribing audit cycle.
2.2  Scenario II: Specialist‑only Prescriptions
Primary care provides the majority of long-term repeat 
prescriptions for chronic conditions [12, 13], but there are 
some medications, particularly medications that require 
close safety monitoring, that are prescribed by specialist 
clinicians. These prescriptions will not appear in primary 
care databases. Over time, prescribing of these medications 
may be transferred to primary care under a “shared-care” 
agreement, whereby the general practice may provide pre-
scriptions while sharing the care of the patient with the spe-
cialist team. In this scenario, a proportion of prescriptions 
will not appear in primary care databases, as a specialist 
may have prescribed the initial prescriptions. These agree-
ments vary geographically based on locally agreed policy 
[14]. Moreover, general practitioners are not obliged to 
agree to shared-care prescribing, in which case, the special-
ist team would continue providing medication prescriptions. 
This scenario can affect primary care prescribing data and 
pharmacovigilance.
Examples of medications that are commonly prescribed 
under shared-care agreements include (1) disease-modifying 
anti-rheumatic drugs (DMARDs), (2) atypical antipsychotic 
medications and (3) cancer treatments.
Some DMARDS used to treat autoimmune conditions 
such as inflammatory bowel disease, rheumatic disease and 
psoriasis require regular monitoring. Examples include 
DMARDs such as azathioprine and methotrexate, which can 
be prescribed in general practice under shared-care arrange-
ments after specialist initiation [12, 13].
Atypical antipsychotic medications such as clozapine 
used to treat resistant schizophrenia are often initiated by 
a specialist psychiatrist in a secondary care setting. Close 
monitoring is required because there is a risk of serious 
side effects such as arrhythmias and agranulocytosis [15]. 
As with DMARDs, once stable, clozapine can be prescribed 
and monitored by general practitioners within local shared-
care prescribing agreements [16].
Cancer treatments such as long-term chemoprophylaxis 
after initial treatment in specialist centres can be prescribed 
in general practice. Examples include tamoxifen when pre-
scribed after breast cancer [17] and gonadotrophin-releasing 
hormone prescribed as part of prostate cancer treatment.
Further examples of medications that may be prescribed 
within a shared-care agreement between specialist and pri-
mary care are tuberculosis and human immunodeficiency 
virus medications, in vitro fertilisation treatment and inject-
able medications such as prescribing for insulin pumps, 
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desferrioxamine and total parenteral nutrition. This is not 
an exhaustive list of medications prescribed under shared-
care agreements, but it does highlight the importance of con-
sidering these cases and their absence from primary care 
databases. Electronic records for secondary or tertiary care 
dispensing data are available for individual, patient-level 
cases in most hospitals, but unlike primary care data, they 
are not yet widely accessible for research purposes to estab-
lish evidenced-based understanding of prescribing practices 
in these settings [18].
2.3  Scenario III: Alternative Community Prescribing 
Such as Pharmacy, Family Planning Clinic 
or Sexual Health Clinic Medication Prescriptions
Health service users in the UK can access family planning 
clinic (FPC) and sexual health clinic (SHC) services directly 
without referrals, and any medications prescribed in these 
settings are not routinely represented in primary care data-
bases. An example is long-acting reversible contraception 
(LARC) prescribing; this contraception can be prescribed 
in both primary care and FPC/SHC, and the latter is not rep-
resented in primary care records. The number of prescrip-
tions issued in primary care versus FPC/SHC is variable. It 
can be influenced by external factors such as government-
backed incentives awarded to general practices, such as 
the Quality Outcomes Framework (QOF), where financial 
incentives are awarded to encourage quality care. Financial 
incentives for LARC prescribing in general practice led to 
more than 100,000 additional primary care prescriptions in 
600 practices, 3 years after these QOF incentives were intro-
duced [19, 20]. Studies that utilise primary care databases to 
investigate medications that can be prescribed in alternative 
community settings must consider the prescribing trends in 
general practice and how these can be influenced by external 
factors such as incentive payments and health campaigns.
In this scenario, we can also consider prescribing by 
community pharmacies. Since 2015/2016, in addition to 
influenza vaccination in primary care settings, the NHS 
has funded the provision of influenza vaccinations to at-
risk groups by community pharmacies [21, 22]. During 
the 2015/2016 flu season, September to March, community 
pharmacies prescribed 486,897 influenza vaccines compared 
with 10,447,651 prescribed in general practice. Those num-
bers increase to 1,524,753 prescribed by community phar-
macies and a slight decrease to 10,326,783 prescribed in 
general practice during the 2019/2020 flu season, based on 
data from  PharmaOutcomes®, Sonar informatics and NHS 
Business Services Authority (NHSBSA) data published 
by the Pharmaceutical Services Negotiating Committee 
(PSNC) and OpenPrescribing.net, EBM DataLab, University 
of Oxford, 2020 [23, 24]. Details of vaccinations provided 
outside general practice in the past have not routinely been 
included in primary care databases. This may have repre-
sented a subset of absent prescriptions in the past, but as 
of December 2020, there have been significant changes in 
the recording and management of immunisation vaccination 
data, due to the current coronavirus disease 2019 (COVID-
19) pandemic. Roll out of the COVID-19 vaccination pro-
gramme has facilitated changes in the recording and man-
agement of immunisation vaccination data in England. The 
centralised service for the management of seasonal influenza 
vaccination programmes has been upgraded to include the 
National Immunisation Vaccination System (NIVS), a web-
based app that is accessible at the point of delivery for real-
time recordings. As a result, COVID-19 vaccinations are 
recorded in the NIVS app or Outcomes4Health (known as 
Pinnacle) web-based system in all community sites, includ-
ing pharmacies and pop-up vaccination sites. An equivalent 
app is also available for secondary care settings, the National 
Immunisation Management System (NIMS). Therefore, all 
vaccinations can be recorded at the point of delivery; these 
data are then sent directly to the general practice EHR or the 
Data Processing Service (DPS) and subsequently recorded 
in primary care databases. This upgraded process is still 
subject to some degree of missingness, but it is expected 
to improve the accessibility, versatility and connectivity of 
primary care databases, this process will capture vaccina-
tion data more effectively than the previous IT systems [25]. 
System changes of this type can influence whether commu-
nity prescribing outside of general practice is recorded in 
primary care prescribing datasets.
2.4  Scenario IV: Newly Licensed Medication 
Prescriptions
New medications may be prescribed by specialist clini-
cians initially, before being prescribed in primary care. 
During this initial period, a proportion of prescriptions 
will be absent from primary care EHR. Novel oral anti-
coagulants (NOACs), medications used to prevent stroke 
and thrombosis, provide an example of this scenario. On 
first introduction to clinical practice in 2008, NOAC pre-
scribing took place in secondary care as post-operative 
prophylaxis [26]. Data show a delay in NOAC prescrib-
ing within primary care until 2012, when National Insti-
tute for Health and Care Excellence (NICE) guidelines 
highlighted the benefits of NOAC use in the management 
of non-valvular atrial fibrillation (AF) [26]. In addition, 
the ARISTOTLE study demonstrated that the NOAC 
apixaban was superior to warfarin at preventing strokes 
in patients with AF [27]. NHS Digital data demonstrate 
that in 2011/2012, 1.10% of all apixaban prescribing by 
the NHS in England was in primary care. By 2013/2014, 
65% of apixaban prescribing occurred in primary care, 
and further increased to 92% by 2017/2018 (Fig. 1) [3]. 
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This trend in NOAC prescribing in primary care has been 
described in various studies [28, 29] and has implica-
tions for pharmacovigilance and pharmacoepidemiol-
ogy studies using these data. Research studies assessing 
newly licensed medication prescribing using primary care 
databases should consider associated prescribing guid-
ance and implementation of guidance by primary care 
clinicians. NHS Digital prescribing data are derived from 
the NHSBSA through the electronic Prescribing Analy-
sis and Cost Tool 2 (ePACT2), which covers all NHS 
general practice prescribing and dispensing in the UK. 
There is no central NHS collection of information on all 
prescribing in NHS hospitals in England, but NHS Digi-
tal does have limited access to some hospital prescribing 
data through organisations such as IQVIA. Hence, NHS 
Digital prescribing data for primary and secondary care 
are not available for all medications [30, 31].
2.5  Scenario V: Medications that Do Not Require 
Prescriptions
Medications that are deemed safe, efficacious and less ame-
nable to misuse can sometimes be available to purchase over 
the counter (OTC) without a prescription. These will not 
appear in primary care databases, and the proportion of any 
particular medication or item that is prescribed versus pur-
chased OTC can change over time. In 2018, the cost of medi-
cines prescribed and dispensed in primary care in England 
reached £9.2 billion [32]. Subsequently, NHS England and 
NHS Clinical Commissioners (NHSCC) devised changes in 
primary care prescribing practices to support a more cost-
effective approach [33]. From April 2019, in accordance 
with national recommendations from NHS England and 
NHSCC, to reduce prescribing for self-limiting conditions 
and encourage people to manage their conditions with self-
care when appropriate, general practices were strongly 
advised to stop routinely prescribing medications that are 
available OTC, such as ibuprofen for minor conditions pre-
senting with pain or fever [34]. Therefore, any study using 
primary care databases involving such medications would 
underestimate their use and potentially be limited by mis-
classification bias.
Prescribing studies that do not include any OTC use of 
non-steroidal anti-inflammatory drugs (NSAIDs) may under-
estimate the risk of adverse events associated with these 
drugs [35–37]. For example, data from the nationwide Dan-
ish Cardiac Arrest Registry showed that in 11.66% of 28,947 
identified cases of out-of-hospital cardiac arrest (OHCA), 
patients had taken either ibuprofen or an alternative NSAID 
within 30 days prior to their OHCA. However, since ibupro-
fen is also available without prescription OTC in Denmark, 
this figure is likely an underestimation of the associated risk 
[36].
Every month, NHS Digital provides anonymised pre-
scribing data from NHS England, which are summarised 
on the open prescribing website https:// openp rescr ibing. net/. 
Figure 2, this website shows a decrease in primary care pre-
scriptions for ibuprofen in England over the last 5 years, an 
overall decline of 52.85 % [24]. This may be indicative of 
increased OTC use of ibuprofen rather than an actual decline 
in use.
2.6  Scenario VI: Hospital Inpatient and Outpatient 
Prescriptions
During hospital admissions and outpatient clinic attend-
ance, patients will have their prescriptions provided by 
their hospital team. These include prescriptions issued in the 
Fig. 1.  The increasing trend in 
prescribing of apixaban, a novel 
oral anticoagulant, by primary 
care clinicians in England 
between 2012 and 2018 [30]. 
NHS National Health Service
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emergency department. One implication is that acute hospi-
tal prescriptions such as intravenous antibiotic prescriptions 
for severe infections are missing from primary care data-
bases. Another implication is that the first record of impor-
tant long-term medications, such as secondary prevention 
medications associated with cardiac events or stroke, e.g. 
clopidogrel prescribed to treat acute presentation of stroke, 
will not appear in primary care databases until up to 90 days 
after the acute event [38].
2.7  Scenario VII: Handwritten Prescriptions
Electronic prescribing systems (EPS) are first-line primary 
care prescribing tools that are integrated with EHRs used in 
England. Handwritten prescriptions are not integrated and are 
used only in exceptional circumstances. There are two nota-
ble reasons for preferential use of EPS: (1) patient safety and 
medicines monitoring, as there is a clear audit trail for root 
cause analysis [39], and (2) security of the prescribing process 
to ensure that prescription details outlined by the prescriber 
cannot be modified or accessed by any unauthorized individ-
uals. All general practices should have a standard operating 
procedure for the use and storage of handwritten prescriptions 
[40]. Electronic prescriptions sent via EPS represent 85% of all 
dispensed prescriptions in primary care [41]. Instances where 
general practices may issue handwritten prescriptions include 
home visits to housebound patients or EPS failure. Although 
prescribers are advised to update the details of any handwrit-
ten prescriptions in EPS retrospectively, this may not always 
occur. In scenarios where handwritten prescriptions have not 
been updated in EPS, the data will not be available in primary 
care databases.
2.8  Scenario VIII: Private Pharmacy and Private 
Doctor Prescriptions
Private prescriptions are not a component of routinely col-
lated data, but there are an increasing number of medical 
prescriptions issued in these settings. Since 2010, a growing 
number of internet-based services supported by private doctors 
have been providing patient care, from acute care (e.g. antibi-
otics) to lifestyle (e.g. recreational use of a phosphodiesterase 
type 5 inhibitor such as sildenafil) medications. Patients who 
can afford to pay and require a service that is not available on 
the NHS or want to avoid NHS waiting times may use this 
service.
In the UK, the NHS provides a routine immunisation 
schedule for endemic infections, but travel vaccines are not 
provided on the NHS. As a result, travel vaccines given pri-
vately may not always be recorded in EHRs. It is important 
to consider private prescriptions in any studies where they 
can affect research study outcomes and conclusions.
3  Implications for Pharmacoepidemiological 
Research, Benefits and Challenges
Primary care databases provide an invaluable resource for 
pharmacoepidemiological studies to inform clinical guide-
lines, pharmacovigilance, public health policy and improve 
the quality of patient care [1, 42]. However, this review 
describes eight key scenarios, summarised in Table  1,   
where absent prescriptions and missing data from primary 
care databases can cause errors in interpretation of study 
outcomes. In descriptive studies that aim to investigate inci-
dence, prevalence and trends in prescribing or drug utilisa-
tion using primary care prescribing data, there will be a clear 
underestimate in the described scenarios. Thus researchers 
should make it clear in their publications that their estimates 
are only applicable to prescribing patterns in general prac-
tice, and should demonstrate awareness of the limitations of 
the data and their implications.
There is no broad overarching solution for addressing this 
missingness of data, and while the described scenarios are 
not an exhaustive list, they cover the more common sce-
narios that may result in misinterpretation of findings.
Fig. 2.  Trends in prescrib-
ing ibuprofen as a product 
or combination product in 
all primary care  servicesa in 
England between March 2016 
and February 2021 [24]. Data 
source: OpenPrescribing.net, 
EBM DataLab, Department of 
Primary Care Health Sciences, 
University of Oxford, 2021. 
NSAID non-steroidal anti-
inflammatory drug. aExcludes 
data from non-standard settings 
such as prisons, the military, 
out-of-hours services, etc.
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The statistical method used to ascertain missingness will 
depend on the drug or item, objectives, study design and 
expected outcome. Multiple imputation of missing data is 
not an option in these scenarios where the prescription data 
missingness can be classified as ‘missing not at random’ 
because we have already explained that there are systematic 
differences between the missing and observed values. On the 
other hand, missing data on the prescription categories we 
have highlighted in these scenarios will mostly lead to non-
differential misclassification of prescription status and could 
lead to a shifting of the relative risk/odds towards null, i.e. 
the observed estimate of an association between an exposure 
and outcome may be an underestimate in hypothesis-testing 
studies investigating the association between prescriptions 
and outcomes. As long as researchers take this into account 
in their interpretation, that should be sufficient, but possible 
solutions for addressing missingness include:
1. Linkage to prescribing data from other healthcare set-
tings where possible. Currently, prescribing data from 
hospitals, out-of-hours services and specialist units are 
not available at a national level. However, data from the 
NHSBSA collated in NHS Digital can provide data on 
the level of prescribing in primary and secondary care 
for only some items, these data are publicly available 
[30, 31]. There is also the Hospital Treatment Insights 
(HTI) dataset, which links Hospital Episode Statis-
tics to pharmacy records for 28.10% of hospital trusts 
in England [43]. This is a partial dataset mostly used 
to understand patient outcomes after treatment, but it 
could be used to estimate prescribing trends when linked 
to primary care datasets. In some instances, it may be 
beneficial to review open-access prescribing datasets 
for primary care prescribing trends [23, 24]. To date, 
there is no database available for aggregate primary and 
secondary care prescribing for all prescribed items in 
England.
2. Supplementing prescribing data from the primary care 
data using study-specific general practitioner and patient 
questionnaires could provide patient-level data on item 
prescribing in all settings, although this may have issues 
regarding anonymity and would require the appropriate 
ethical considerations and general data protection regu-
lations.
An understanding of the strengths and limitations of pri-
mary care prescribing data is required for all studies and 
investigations using this data for research purposes.
4  Conclusion
The NHS is a UK-wide universal healthcare system, and > 
95% of UK residents are registered with a general practice 
[44]. EHRs from general practice used to generate primary 
care databases are likely to remain an important research 
resource, driving quality improvement at the patient and 
population level. Although the scenarios described in this 
review highlight limitations of using primary care databases 
for pharmacovigilance and pharmacoepidemiological stud-
ies involving some medications in the UK, they also provide 
insights to inform study design and interpretation of data to 
yield more reliable and useful conclusions.
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